The study was terminated for strategic reasons

The main purpose of this study is to investigate Lu AG06466 as a treatment for spasticity in participants with multiple sclerosis (MS).

The participants will be randomized to Lu AG06466 or placebo in a 2:1 ratio.

Key Inclusion Criteria:

• The participant has a diagnosis of MS, as per the 2017 McDonald criteria.
• The participant has clinically stable MS (such as no relapse and/or stable Expanded Disability Status Scale [EDSS] or alternative clinical assessment score) for at least 6 months prior to screening.
• The participant has ongoing spasticity for at least 90 days prior to screening.
• The participant is on a stable regimen for at least 30 days prior to screening for all medications and non pharmacological therapies, including therapies that are intended to alleviate spasticity (for example, oral baclofen, tizanidine, dalfampridine), and willing to remain on the same regimen throughout the duration of the study.
• The participant reports walking impairment due to lower limb spasticity.

Key Exclusion Criteria:

• The participant has any concomitant disease or disorder that has spasticity-like symptoms or that may influence the participant's level of spasticity or the participant's overall ability to participate in the study.
• The participant has ambulation difficulties due to any concomitant disease or disorder other than MS.
• The participant has any known or suspected hypersensitivity to cannabinoids (CBs) or any of the excipients of the investigational medicinal product (IMP).
• The participant has a positive drug screening test, except for non-CB medications used to treat a medical condition and reported as such by the participant; the participant has a positive drug screen test for cannabis/delta-9-tetrahydrocannabinol.

Other inclusion and exclusion criteria may apply.